Aug 17, 2016
ICER has come out with a response to what it defines as myths about it’s funding, approach and mission. The rejoinder is an excellent example of President Kennedy’s observation that “the great enemy of the truth is very often not the lie, deliberate, contrived and...
Jul 24, 2016
As I have previously discussed, ICER’s initiative to revisit the representatitiveness and scientific validity of his QALY based assessments of drug prices and access is really a crude political makeover. The recent appointment of so-called patient and consumer...
Jun 25, 2016
After concluding that because myeloma drugs keep people alive longer they cost too much to be cost-effective, ICER through it’s Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC) is now looking at new drugs for treating people with non small...
Jun 18, 2016
This post on ICER from a patient’s perspective is by Don Wright. Don is a lawyer living and working in Minnesota and has been running marathons since 2002. In 2003 he was diagnosed with multiple myeloma, a blood cancer with no cure. He went on an...
Jun 8, 2016
Peter Loftus’ article Combination Drug Therapies for Cancer Show Promise at Higher Potential Cost relies on opinion rather than facts. And the opinion he relies on comes from an organization that combines factoids with fiction to demonstrate that new drugs are...
